Artiva Biotherapeutics, Inc. (ARTV)
US — Healthcare Sector
Automate Your Wheel Strategy on ARTV
With Tiblio's Option Bot, you can configure your own wheel strategy including ARTV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARTV
- Rev/Share 0.0
- Book/Share 6.1135
- PB 0.7222
- Debt/Equity 0.0887
- CurrentRatio 13.8434
- ROIC -0.4917
- MktCap 107839739.0
- FreeCF/Share -2.9046
- PFCF -1.5229
- PE -1.577
- Debt/Assets 0.0781
- DivYield 0
- ROE -0.387
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ARTV | H.C. Wainwright | -- | Buy | -- | $12 | June 11, 2025 |
| Initiation | ARTV | H.C. Wainwright | -- | Buy | -- | $20 | Dec. 30, 2024 |
News
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
ARTV
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis
Read More
About Artiva Biotherapeutics, Inc. (ARTV)
- IPO Date 2024-07-19
- Website https://www.artivabio.com
- Industry Biotechnology
- CEO Fred Aslan
- Employees 96
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.